Drug delivery news roundup
Prosonix says its UMAX technology has significantly improved targeted drug delivery in the lungs by combining two inhaled respiratory molecules within multi-component particles (MCP).
In the new research, the Oxford, UK based firm combined budesonide (BDS) and formoterol fumarate dihydrate (FFD) in a single particle.
Using Raman chemical imaging after delivery, the combined particles showed optimal co-association and co-localisation of the drug molecules at the correct sites in the lung and respiratory tract.
The result - a pre-determined ratio with control and consistency.
David Hipkiss, Prosonix’ CEO, said: “Using proven respiratory medicines in combination potentially offers patients the best option for treating pulmonary disease.
“We are very excited to have demonstrated that our UMAX technology can create multi-component particles that consistently and predictably co-localise inhaled corticosteroids (ICS) and long-acting β2-adrenergic bronchodilators (LABA) in the lung.
“Developing this area of our business is important for our future growth as we aim to build a pipeline of next-generation combination medicines (our PSX2000 series) offering multiple benefits to patients such as enhanced efficacy, true synergy, fewer side effects and improved compliance.”
In other respiratory delivery news, Aptar Pharma has unveiled the latest in its line of DF30 metering valvetechnologies for Pressurized Metered-Dose Inhalers (pMDIs).
The firm says its DF30Plus - which allows a controlled quantity of medication to be released from inhaler devices – now offers better compatibility across a wider range of drug formulations, including those containing ethanol.
And in a statement from the company, a spokesperson said the valve also has “excellent pressure filling capability.”
“DF30Plus is the result of innovation and continuous improvement to the technology platform range and provides several new benefits,” said Chris Baron, associate director of business development for Aptar’s pharma prescription division.
And finally, Apricus Biosciences has been given the go-ahead from the Japanese patent office for its crystalline salt delivery technology.
The firm uses the salts in its NexACT(R) permeation enhancer technology, for topical drug delivery.
It says the salts have improved its platform’s compatability, water solubility and permeation profiles.
Bassam Damaj, chairman, president and CEO of Apricus, said: "We are delighted to receive this additional important patent in Japan for our NexACT(R) technology and related products.
“The receipt of this patent represents an important step in solidifying our drug delivery technology, which enables multi-route administration of new and improved compounds across numerous therapeutic classes.”
The company is now seeking Japanese partners for the development and commercialisation of the platform.
